Investment Portfolio
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
- Project highlight: The world's first commercialized 3D navigation/GPS company for intraoperative management, providing physicians with a safe, real-time imaging solution that significantly improves clinical outcomes, lowers costs and reduces radiation time for patients and caregivers during surgery.
- Investment stage: Series B round
- Project
- Project highlight: The world's first commercialized 3D navigation/GPS company for intraoperative management, providing physicians with a safe, real-time imaging solution that significantly improves clinical outcomes, lowers costs and reduces radiation time for patients and caregivers during surgery.
- Investment stage: Series B round
- Project update: Completed B round financing of $30M, led by Cleveland clinic fund. The company's product has been used in many well-known hospitals such as Cleveland clinics, Allegheny general, university of Maryland medical center, university Virginia, etc.
CarslMed: Individualized treatment plan for adult spinal deformity
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
- Project highlight: The world's first company that uses artificial intelligence and 3D printing technology to provide customized treatment plans for adult spinal deformities
- Investment stage: Seed round joint lead investment, continue to participate in Series A round
- Project update: Completed B round financing of $33M in 2022
Leo Cancer Care: Upright radiotherapy solution
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
Smartlens: Convenient and affordable treatment for Glaucoma
- Project highlight: The world's first supplier of upright radiotherapy equipment with lower cost and fewer side effects on patients.
- Investment stage: Series B round
- Project update: July 2021, Leo Cancer Care raised $25.3m in Series B funding. Investors included Pureland Global Venture, Yu Galaxy, WARF, Alumni Ventures, Junson Capital and Se
- Project highlight: The world's first supplier of upright radiotherapy equipment with lower cost and fewer side effects on patients.
- Investment stage: Series B round
- Project update: July 2021, Leo Cancer Care raised $25.3m in Series B funding. Investors included Pureland Global Venture, Yu Galaxy, WARF, Alumni Ventures, Junson Capital and Serra Ventures as well as industry leaders CHC, Cosylab, Toret Devices and Radiation Business Solutions.
Smartlens: Convenient and affordable treatment for Glaucoma
Smartlens: Convenient and affordable treatment for Glaucoma
Smartlens: Convenient and affordable treatment for Glaucoma
- Project highlight: The first device capable of monitoring IOP as a non-invasive, easy to use, electronics-free, and low-cost solution giving doctors a better tool for Glaucoma management.
- Investment stage: Pre-A round
- Project update: Recently, Smartlens raised $3M for its Pre-A funding. Investors included Sophia Pharmaceuticals and Fund of Glaucoma Associates of Texas.
Deepvoxel: AI-driven medical imaging diagnosis technology
Smartlens: Convenient and affordable treatment for Glaucoma
Deepvoxel: AI-driven medical imaging diagnosis technology
- Project highlight: The only software product in this field that provides customers with customized organ-at-risk (OAR) automatic delineation based on AI technology.
- Investment stage: Seed round
- Project update: The company has established commercial cooperation with five hospitals, including City of Hope and Hoag Hospital. It is planned to cooperate with more than 10 hospitals by the end of 2021.
iDENTICAL: 3D dental implant
Smartlens: Convenient and affordable treatment for Glaucoma
Deepvoxel: AI-driven medical imaging diagnosis technology
- Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
- Investment stage: Seed round
- Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be us
- Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
- Investment stage: Seed round
- Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be used to support the pilot and pivotal clinical studies and 510(k) clearance.
Perceptive Medical: Blood pressure management system
Cari Health: The first wearable device for monitoring opioid addiction
Telesair: Respiratory care equipment for lung diseases
- Project highlight: Using the world's first breakthrough technology to solve the problem of inefficient blood pressure management in the intensive care unit (ICU) and operating room.
- Investment stage: Seed round
- Project update: Completed seed round of financing and raised $1.15M for equipment design and prototype design.
Telesair: Respiratory care equipment for lung diseases
Cari Health: The first wearable device for monitoring opioid addiction
Telesair: Respiratory care equipment for lung diseases
- Project highlight: Developed the market-leading next-generation respiratory care equipment that is safer and more efficient for use in clinics and homes.
- Investment stage: Seed round and A round
- Project update: Completed A round financing of $22M, including $3M from strategic investor Honeywell.
Cari Health: The first wearable device for monitoring opioid addiction
Cari Health: The first wearable device for monitoring opioid addiction
Eximius Diagnostics: Detection of early-stage liver cancer with nano-exosomes
- Project highlight: The nation's first device for monitoring opioid addiction, one of the top ten important medical challenges in the United States, and the market is huge. The project was funded by NIH with $4M.
- Investment stage: Seed round
Eximius Diagnostics: Detection of early-stage liver cancer with nano-exosomes
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
Eximius Diagnostics: Detection of early-stage liver cancer with nano-exosomes
- Project highlight: The company's products have made a breakthrough in the detection of early-stage liver cancer with nano-exosomes. The clinical trials of the products were carried out in UCLA medical center and Cedars-Sinal medical center, and the clinical effect was obvious. This project has received more than 20 million grants from NIH
- Project highlight: The company's products have made a breakthrough in the detection of early-stage liver cancer with nano-exosomes. The clinical trials of the products were carried out in UCLA medical center and Cedars-Sinal medical center, and the clinical effect was obvious. This project has received more than 20 million grants from NIH.
- Investment stage: Seed round
- Project update: The company just received BDD (breakthrough designation device) from FDA.
Paloma: The only female thyroid disease telemedicine platform in the U.S.
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
- Project highlight: The number of potential female thyroid patients in the United States has reached 25 million, creating huge business opportunity for the platform. It has provided medical services to more than 20,000 people and the users are keep growing rapidly.
- Investment stage: Series A round
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
- Project highlight: The first American provider of robot-assisted, minimally invasive solutions for TBM (Tracheobronchomalacia) treatment.The company already had 150 successfully minimally invasive procedures with significant improvements in PF and SGRQ.FDA 510K clearance anticipated with commercial readiness Q1 2024.
- Investment stage: Pre-A round
Neurava: Intelligent monitoring products for epilepsy and SUDEP risk
Neurava: Intelligent monitoring products for epilepsy and SUDEP risk
Neurava: Intelligent monitoring products for epilepsy and SUDEP risk
- Project highlight: The first U.S. company offering intelligent monitoring products for epilepsy and SUDEP risk, especially early warning for SUDEP risk. The company expects to get 510(k) clearance for arm wearable in Q4 2023, and 510(k) clearance for neck wearable in Q2 2024.
- Investment stage: Seed round
Modality.ai: Assessing neurological and psychiatric state
Neurava: Intelligent monitoring products for epilepsy and SUDEP risk
Neurava: Intelligent monitoring products for epilepsy and SUDEP risk
- Project highlight: The first automated, clinically validated, multimodal system to assess neurological and psychiatric states. The company has provided services to three of the top 10 pharmaceutical companies, and it recently signed a $2.8 million collaboration agreement with a biopharmaceutical company.
- Investment stage: Seed round
3EO: Developing high-performing low-cost molecular diagnostics
Neurava: Intelligent monitoring products for epilepsy and SUDEP risk
Bright Uro: Novel wireless,catheter-free urodynamic monitoring system
- Project highlight: The first product on the market to provide high-precision point-of-care molecular testing at the price of an antigen test. Clinical trials show 99% accuracy, 95% PPA, and 100% NPA. The product has been approved by FDA for marketing. Strong market demand.
- Investment stage: Series A round
Bright Uro: Novel wireless,catheter-free urodynamic monitoring system
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
Bright Uro: Novel wireless,catheter-free urodynamic monitoring system
- Project highlight: Developing the urinary motility monitoring system/hardware and software with high level of comfortability, accuracy, and efficiency. The company’s patent is licensed from the Cleveland Clinic. The current urinary motility monitoring market is an insufficient market with low penetration rate, and there is huge room for d
- Project highlight: Developing the urinary motility monitoring system/hardware and software with high level of comfortability, accuracy, and efficiency. The company’s patent is licensed from the Cleveland Clinic. The current urinary motility monitoring market is an insufficient market with low penetration rate, and there is huge room for development. Laborie Medical Technologies, a leading global provider of urology diagnostic and therapeutic solutions, led Series A round of investment with $5M as a strategic investor.
- Investment stage: Series A round
ImmeersiveTouch: A real time,hands-on surgical planning software via 3D/VR model
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
- Project highlight: A groundbreaking, FDA-510(k) cleared planning software that provides a real time,hands-on surgical planning experience using patient-specific anatomy. The company has obtained 4 FDA marketing approvals and European CE marketing approval. The product has been deployed in more than 40 hospitals, and till now there have be
- Project highlight: A groundbreaking, FDA-510(k) cleared planning software that provides a real time,hands-on surgical planning experience using patient-specific anatomy. The company has obtained 4 FDA marketing approvals and European CE marketing approval. The product has been deployed in more than 40 hospitals, and till now there have been 3,000 patient clinical cases.
- Investment stage: Bridge B round
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
- Project highlight: The company‘s platform utilizes generative AI + high-throughput digital biology to usher in a new era of data-driven innovative drug discovery. The company has developed a data-driven dry wet closed-loop intelligent drug discovery platform by combining its unique high-throughput single-cell functional screening (AuraLow
- Project highlight: The company‘s platform utilizes generative AI + high-throughput digital biology to usher in a new era of data-driven innovative drug discovery. The company has developed a data-driven dry wet closed-loop intelligent drug discovery platform by combining its unique high-throughput single-cell functional screening (AuraLowTM), synthetic biology-based protein hypermutation automatic evolution (AuraQuestTM), and protein language and structure-inspired generative AI big model (AuraPicassoTM).
- Investment stage: Seed round
